S&P DJI Announces March 2024 Quarterly Rebalance
Filed with ASX · · 8 pages · English
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Botanix Pharmaceuticals Half Year Report
- December 2023 Quarterly Activities Report and Appendix 4C
- NDA Resubmission Accepted and Approval Date Confirmed
- Botanix Resubmission of NDA for Sofdra Completed
- Successful Completion of Human Factors Study
Later from Botanix Pharmaceuticals
- March 2024 Quarterly Activities Report and Appendix 4C
- Final Sofdra Labelling Discussions with FDA
- FDA Approves Sofdra
- Botanix $70 Million Institutional Capital Raising
- June 2024 Quarterly Activities Report and Appendix 4C
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals